The results of this study demonstrate that any irAEs are predictive of survival in patients with NSCLC expressing PDL1 ≥ 50% treated with pembrolizumab, but that these associations are restricted to subsets of irAEs. This evidence concerns the gene CD274 and non-small cell lung carcinoma.